🇺🇸 HALO — Halozyme Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

128,62 USD

Máx. histórico

131,18

5 días

Caída desde máximo

-1,95%

Rango 52 semanas

61,23 – 134,00

Variación hoy

-0,26%

Cierre anterior

128,95

Rango de hoy

128,26 – 131,36

Volumen hoy

1.412.955

Peor caída histórica

-74,26%

05/06/2007 → 04/12/2008

Recuperado en 1154 días

Volatilidad anualizada ⓘ

57,99%

Información
Nombre completo
Halozyme Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
423
PER ⓘ
37,61 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
108,89 USD (puede no estar actualizado)
Primera cotización
16/03/2004
Precio actualizado
hace 13 horas
Sobre la empresa

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
26/07/2024 56,08 57,09 55,63 56,23 +0,46% 2,60% 831.900
25/07/2024 55,60 56,97 55,48 55,97 +1,49% 2,68% 1.017.100
24/07/2024 55,02 55,68 54,54 55,15 -0,45% 2,07% 970.900
23/07/2024 54,34 56,50 54,05 55,40 +1,95% 4,51% 1.387.200
22/07/2024 54,27 54,42 53,13 54,34 +0,56% 2,38% 1.057.100
19/07/2024 54,55 54,59 53,66 54,04 -0,48% 1,70% 778.400
18/07/2024 54,64 55,46 53,85 54,30 -0,82% 2,95% 1.014.600
17/07/2024 54,58 55,82 54,43 54,75 -0,64% 2,55% 1.383.000
16/07/2024 52,90 55,29 52,55 55,10 +4,85% 5,18% 1.826.400
15/07/2024 53,20 53,30 52,12 52,55 -1,18% 2,22% 1.391.100
12/07/2024 53,70 53,96 53,04 53,18 +0,68% 1,71% 1.265.200
11/07/2024 54,00 54,00 52,46 52,82 -0,26% 2,85% 1.299.800
10/07/2024 52,92 53,75 52,67 52,96 +0,15% 2,04% 1.586.700
09/07/2024 52,55 54,35 52,24 52,88 +0,63% 4,02% 2.036.700
08/07/2024 51,83 53,17 51,56 52,55 +1,92% 3,11% 1.634.600
05/07/2024 52,05 52,50 51,36 51,56 -0,87% 2,19% 742.100
03/07/2024 51,46 52,42 50,93 52,01 +1,38% 2,90% 839.300
02/07/2024 51,95 52,11 50,68 51,30 -1,38% 2,75% 1.039.700
01/07/2024 52,23 53,22 51,53 52,02 -0,65% 3,24% 1.364.200
28/06/2024 51,84 52,59 51,24 52,36 +1,41% 2,60% 2.334.600
27/06/2024 52,25 52,35 51,53 51,63 -0,71% 1,57% 874.800
26/06/2024 52,06 52,13 51,33 52,00 -0,76% 1,54% 1.171.700
25/06/2024 52,49 52,68 51,81 52,40 +0,65% 1,66% 1.121.300
24/06/2024 52,40 52,92 51,72 52,06 +0,99% 2,29% 1.278.800
21/06/2024 51,12 52,21 50,82 51,55 +1,36% 2,72% 3.532.100
20/06/2024 50,11 51,19 49,45 50,86 +1,17% 3,47% 1.154.700
18/06/2024 49,74 50,84 49,00 50,27 +1,23% 3,70% 1.035.300
17/06/2024 49,48 49,70 48,25 49,66 +0,32% 2,93% 1.007.300
14/06/2024 49,10 49,77 48,50 49,50 -0,24% 2,59% 1.418.000
13/06/2024 49,32 49,91 48,86 49,62 -0,08% 2,13% 1.363.800